301 related articles for article (PubMed ID: 36980226)
1. Monocyte and Macrophage in Neuroblastoma: Blocking Their Pro-Tumoral Functions and Strengthening Their Crosstalk with Natural Killer Cells.
Vitale C; Bottino C; Castriconi R
Cells; 2023 Mar; 12(6):. PubMed ID: 36980226
[TBL] [Abstract][Full Text] [Related]
2. Anti-CD105 Antibody Eliminates Tumor Microenvironment Cells and Enhances Anti-GD2 Antibody Immunotherapy of Neuroblastoma with Activated Natural Killer Cells.
Wu HW; Sheard MA; Malvar J; Fernandez GE; DeClerck YA; Blavier L; Shimada H; Theuer CP; Sposto R; Seeger RC
Clin Cancer Res; 2019 Aug; 25(15):4761-4774. PubMed ID: 31068371
[TBL] [Abstract][Full Text] [Related]
3. GD2 redirected CAR T and activated NK-cell-mediated secretion of IFNγ overcomes MYCN-dependent IDO1 inhibition, contributing to neuroblastoma cell immune escape.
Caforio M; Sorino C; Caruana I; Weber G; Camera A; Cifaldi L; De Angelis B; Del Bufalo F; Vitale A; Goffredo BM; De Vito R; Fruci D; Quintarelli C; Fanciulli M; Locatelli F; Folgiero V
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33737337
[TBL] [Abstract][Full Text] [Related]
4. Transition to a mesenchymal state in neuroblastoma may be characterized by a high expression of GD2 and by the acquisition of immune escape from NK cells.
Di Matteo S; Bilotta MT; Pelosi A; Haas D; Theinert T; Weber G; Schlegel PG; Berg M; Moretta L; Maggi E; Azzarone B; Vacca P; Tumino N; Caruana I
Front Immunol; 2024; 15():1382931. PubMed ID: 38736882
[TBL] [Abstract][Full Text] [Related]
5. Identification of neuroblastoma cell lines with uncommon TAZ
Canzonetta C; Pelosi A; Di Matteo S; Veneziani I; Tumino N; Vacca P; Munari E; Pezzullo M; Theuer C; De Vito R; Pistoia V; Tomao L; Locatelli F; Moretta L; Caruana I; Azzarone B
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33452207
[TBL] [Abstract][Full Text] [Related]
6. Fenretinide sensitizes multidrug-resistant human neuroblastoma cells to antibody-independent and ch14.18-mediated NK cell cytotoxicity.
Shibina A; Seidel D; Somanchi SS; Lee DA; Stermann A; Maurer BJ; Lode HN; Reynolds CP; Huebener N
J Mol Med (Berl); 2013 Apr; 91(4):459-72. PubMed ID: 23052481
[TBL] [Abstract][Full Text] [Related]
7. Exploring the potential of combining IL-2-activated NK cells with an anti-PDL1 monoclonal antibody to target multiple myeloma-associated macrophages.
Ehlers FAI; Mahaweni NM; van de Waterweg Berends A; Saya T; Bos GMJ; Wieten L
Cancer Immunol Immunother; 2023 Jun; 72(6):1789-1801. PubMed ID: 36656341
[TBL] [Abstract][Full Text] [Related]
8. Enhancing Neuroblastoma Immunotherapies by Engaging iNKT and NK Cells.
McNerney KO; Karageorgos SA; Hogarty MD; Bassiri H
Front Immunol; 2020; 11():873. PubMed ID: 32457760
[TBL] [Abstract][Full Text] [Related]
9. Combinatorial immunotherapy of N-803 (IL-15 superagonist) and dinutuximab with ex vivo expanded natural killer cells significantly enhances in vitro cytotoxicity against GD2
Chu Y; Nayyar G; Jiang S; Rosenblum JM; Soon-Shiong P; Safrit JT; Lee DA; Cairo MS
J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34244307
[TBL] [Abstract][Full Text] [Related]
10. The role of interleukin-2, all-trans retinoic acid, and natural killer cells: surveillance mechanisms in anti-GD2 antibody therapy in neuroblastoma.
Nguyen R; Houston J; Chan WK; Finkelstein D; Dyer MA
Cancer Immunol Immunother; 2018 Apr; 67(4):615-626. PubMed ID: 29327110
[TBL] [Abstract][Full Text] [Related]
11. Redefining Tumor-Associated Macrophage Subpopulations and Functions in the Tumor Microenvironment.
Wu K; Lin K; Li X; Yuan X; Xu P; Ni P; Xu D
Front Immunol; 2020; 11():1731. PubMed ID: 32849616
[TBL] [Abstract][Full Text] [Related]
12. Targeting macrophage Syk enhances responses to immune checkpoint blockade and radiotherapy in high-risk neuroblastoma.
Rohila D; Park IH; Pham TV; Jones R; Tapia E; Liu KX; Tamayo P; Yu A; Sharabi AB; Joshi S
Front Immunol; 2023; 14():1148317. PubMed ID: 37350973
[TBL] [Abstract][Full Text] [Related]
13. Small extracellular vesicles induce resistance to anti-GD2 immunotherapy unveiling tipifarnib as an adjunct to neuroblastoma immunotherapy.
Liu X; Wills CA; Chen L; Zhang J; Zhao Y; Zhou M; Sundstrom JM; Schell T; Spiegelman VS; Young MM; Wang HG
J Immunother Cancer; 2022 Apr; 10(4):. PubMed ID: 35483745
[TBL] [Abstract][Full Text] [Related]
14. Dual roles of HK3 in regulating the network between tumor cells and tumor-associated macrophages in neuroblastoma.
Wu X; Mi T; Jin L; Ren C; Wang J; Zhang Z; Liu J; Wang Z; Guo P; He D
Cancer Immunol Immunother; 2024 May; 73(7):122. PubMed ID: 38714539
[TBL] [Abstract][Full Text] [Related]
15. Immune checkpoint molecules in neuroblastoma: A clinical perspective.
Pathania AS; Prathipati P; Murakonda SP; Murakonda AB; Srivastava A; Avadhesh ; Byrareddy SN; Coulter DW; Gupta SC; Challagundla KB
Semin Cancer Biol; 2022 Nov; 86(Pt 2):247-258. PubMed ID: 35787940
[TBL] [Abstract][Full Text] [Related]
16. Tumour-associated macrophages as a potential target to improve natural killer cell-based immunotherapies.
Kitamura T
Essays Biochem; 2023 Sep; 67(6):1003-1014. PubMed ID: 37313600
[TBL] [Abstract][Full Text] [Related]
17. Unlicensed NK cells target neuroblastoma following anti-GD2 antibody treatment.
Tarek N; Le Luduec JB; Gallagher MM; Zheng J; Venstrom JM; Chamberlain E; Modak S; Heller G; Dupont B; Cheung NK; Hsu KC
J Clin Invest; 2012 Sep; 122(9):3260-70. PubMed ID: 22863621
[TBL] [Abstract][Full Text] [Related]
18. Lenalidomide overcomes suppression of human natural killer cell anti-tumor functions by neuroblastoma microenvironment-associated IL-6 and TGFβ1.
Xu Y; Sun J; Sheard MA; Tran HC; Wan Z; Liu WY; Asgharzadeh S; Sposto R; Wu HW; Seeger RC
Cancer Immunol Immunother; 2013 Oct; 62(10):1637-48. PubMed ID: 23982484
[TBL] [Abstract][Full Text] [Related]
19. Cytokines Orchestrating the Natural Killer-Myeloid Cell Crosstalk in the Tumor Microenvironment: Implications for Natural Killer Cell-Based Cancer Immunotherapy.
Gaggero S; Witt K; Carlsten M; Mitra S
Front Immunol; 2020; 11():621225. PubMed ID: 33584718
[TBL] [Abstract][Full Text] [Related]
20. NK Cell-derived Exosomes From NK Cells Previously Exposed to Neuroblastoma Cells Augment the Antitumor Activity of Cytokine-activated NK Cells.
Shoae-Hassani A; Hamidieh AA; Behfar M; Mohseni R; Mortazavi-Tabatabaei SA; Asgharzadeh S
J Immunother; 2017 Sep; 40(7):265-276. PubMed ID: 28622272
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
